A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Inclusion Criteria: * Advanced or recurrent unresectable gastric or GEJ cancer * Histologically confirmed adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma or poorly differentiated adenocarcinoma), signet-ring cell carcinoma, mucinous adenocarcinoma or hepatoid adnocarcinoma * Patients with normal oral intake * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Patients who have measurable target lesion * Patients has a refractory or intolerant pretreatment by pyrimidine fluoride anticancer agent and platinum-based anticancer agent * Patients with adequate organ function * Patients with no pretreatment history including ramucirumab, nivolumab or other therapies targeting control of T cells * Patients with written informed consent Exclusion Criteria: * Patients have double cancer * Patients have infection required systemic therapy * Known central vervous system (CNS) metastasis * Patients with history of pneumonitis or pulmonary fibrosis * Patients with history of serious anaphylaxis induced by antibody preparation * Patients who have known active autoimmune disease or history of chronic recurrent autoimmune disease * Female who is pregnant, lactating or suspected pregnancy * Patients with psychosis or dementia to interfere to obtain informed consent appropriately